cart

0

Total:

USD 0.00

Dear customer, your shopping cart is empty.
Start shopping now!

Use discount
 

Error! Coupon is not valid

Maybe you entered wrong code of coupon

Entered coupon Activated

PRODUCT CATEGORIES

View all categories

Daklinza (Daclatasvir)

Daklinza
Customer rating:

4.4 out of 5(645 reviews)

5

(440)

4

(110)

3

(49)

2

(28)

1

(18)

Product Info:

Category: Anti-Hepatitis

Brand: Daklinza

Price: per bottle

Savings:

In Stock: Yes

Other names for this medication:

Quantity:

Subtotal: USD 547.05

Add to cart
  • General Info

    Daklinza is an antiviral drug indicated as a part of concomitant therapy of chronic hepatitis C virus (HCV) infection in patients with either compensated or decompensated liver disease (including cirrhosis). The medication is a direct agent against chronic HCV genotype 1 or 3 and is to be used with other medicines to prevent multiplication and spread of the virus in the body. Daklinza is appropriate for administration in adults 18 years of age and over.

    Similar Products:

    Copegus, Rebetol

    Active Ingredient:

    Daclatasvir

    Description

    Daklinza is a direct-acting antiviral medicine indicated for the treatment of a long-term infection caused by the hepatitis C virus (HCV) genotype 1 or 3 in patients with compensated or decompensated liver disease. It is used exclusively as a part of a concomitant HCV treatment with such medicines as Sofosbuvir and Ribavirin.

    The medication contains the active ingredient Daclatasvir which belongs to a group of drugs called nonstructural protein 5A (NS5A) complex inhibitors. It works by preventing the hepatitis C virus from copying itself and infecting liver cells. This helps to decrease the amount of the virus in the body and promotes its removal from the human blood over a period of time.

    Daklinza is only effective in combination with other antiviral agents and at evenly spaced intervals. Together they help the immune system fight the infection and promote recovery and better functioning of the liver. Patients should be aware that anti-hepatitis C combination treatment does not prevent from passing the virus to the others. In order to lower such a risk, needle sharing or/and practice of ‘unsafe sex’ (without any contraceptive measures) should be avoided.

    Indications

    Concomitant treatment of patients with chronic HCV genotypes 1 and 3 infections with/without compensated or decompensated liver disease (including cirrhosis).

    MOA (mechanism of action)

    Daclatasvir is a first-in-class HCV NS5A replication complex inhibitor and a selective direct-acting antiviral (DAA) agent. The active substance exerts the ability of binding to HCV RNA and interfering with the activity of a nonstructural protein 5A (NS5A), a vital component for the hepatitis C virus replication process. This leads to an inhibition of the two HCV life cycle stages - viral RNA replication and virion assembly which results in the viral RNA chain termination.

    Dosage

    Treatment with Daklinza should be initiated and monitored by a doctor for each individually. Before starting the therapy, patients should be tested for the evidence of current or prior hepatitis B virus (HBV) infection and/or any drug resistance. Daklinza is to be taken orally with or without food. The tablets must be swallowed whole with a glassful of water. Do not chew or crush them.

    Maximum daily dose of Daklinza for genotype 1 or 3 HCV infection - 90 mg.

    In regimens of chronic HCV infection treatment, the medicine may be administered with or without Ribavirin. When taken with, the dosing should be advised and adjusted by a doctor basing on a patient’s hemoglobin levels and creatinine clearance as well as on the body weight. However, if the administration of Sofosbuvir is discontinued in those receiving Daclatasvir together with Sofosbuvir, then Daclatasvir intake should be ceased too. Avoid stopping any drugs intake too early as it may result in the infection retrieval.

    Missed dose

    If you miss a dose of Daklinza you should take it as soon as you remember. If it is the time for the next dose you should continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

    Overdose

    If an overdose occurs and you are feeling unwell, you should seek emergency medical attention or contact your healthcare provider immediately.

    Storage

    Store at room temperature between 20°C and 25°C (68°F and 77°F) away from excess moisture and heat. Do not use the medication if the seal is missing or broken. Keep the bottle tightly closed. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

  • Safety Information

    Daklinza is an antiviral drug indicated as a part of concomitant therapy of chronic hepatitis C virus (HCV) infection in patients with either compensated or decompensated liver disease (including cirrhosis). The medication is a direct agent against chronic HCV genotype 1 or 3 and is to be used with other medicines to prevent multiplication and spread of the virus in the body. Daklinza is appropriate for administration in adults 18 years of age and over.

    Similar Products:

    Copegus, Rebetol

    Active Ingredient:

    Daclatasvir

    Side effects

    The most common side effects associated with Daklinza are:

    • headache
    • dizziness
    • fatigue
    • confusion
    • insomnia
    • nausea
    • diarrhea
    • vomiting
    • constipation
    • abdominal pain
    • decreased appetite
    • low red blood cell count (anemia)
    • slow heart rate (bradycardia)
    • shortness of breath
    • cough
    • chest pain
    • allergic reactions (dry skin, rash, itching)
    • muscle and joint pain

    Side effect occurrence does not only depend on medication you are taking but also on your overall health and other factors.

    Contraindications

    Do not use Daklinza in patients with known hypersensitivity to Daclatasvir or any of the drug's excipients.

    Do not take the medication as a monotherapy for the chronic hepatitis C virus (HCV) treatment.

    Do not use the drug if you have been infected with hepatitis B virus (HBV) as the treatment of chronic HCV infection may increase the replication of HBV.

    Do not give the tablets to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

    Do not take the medicine if you are pregnant or breastfeeding unless recommended by your doctor.

    Do not give Daklinza to patients younger than 18 years of age without a doctor’s advice.

    Do not co-administrate Daklinza with any of the following medications:

    • anticonvulsants (e.g., carbamazepine, eslicarbazepine, fosphenytoin, phenytoin, phenobarbital, oxcarbazepine, pentobarbital, primidone)
    • medicines for the treatment of tuberculosis (such as rifampicin, rifabutin or rifampin)
    • cardiovascular drugs (amiodarone)
    • steroids used to treat allergic and inflammatory diseases (as dexamethasone)
    • medications containing St John's wort
    • some other drugs (like dabrafenib, enzalutamide, lumacaftor, mitotane, nevirapine)

    Caution should be exercised when Daklinza is taken concomitantly with P-gp, OATP 1B1 or 1B3, or BCRP as it may increase or prolong the therapeutic effect of these drugs and/or increase chances for side effects occurrence.

  • F.A.Q.

    Daklinza is an antiviral drug indicated as a part of concomitant therapy of chronic hepatitis C virus (HCV) infection in patients with either compensated or decompensated liver disease (including cirrhosis). The medication is a direct agent against chronic HCV genotype 1 or 3 and is to be used with other medicines to prevent multiplication and spread of the virus in the body. Daklinza is appropriate for administration in adults 18 years of age and over.

    Similar Products:

    Copegus, Rebetol

    Active Ingredient:

    Daclatasvir

    Q: What is the medication used for?

    A: Daklinza is an antiviral agent utilized as a part of combination therapy for the treatment of chronic hepatitis C virus (HCV) infection (genotype 1 or 3) in patients suffering from either compensated or decompensated liver disease (including cirrhosis).

    Q: How should I take the drug?

    A: The initiation of the treatment with Daklinza must be advised by a doctor according to certain blood tests. It should only be used in combination with other antiviral medicines. The medication is to be taken orally with a glassful of water regardless of food intake. The tablets must be swallowed whole without chewing or crushing.

    Q: Is it safe to take if pregnant or when breastfeeding?

    A: Daklinza administration in pregnant or breastfeeding women is not recommended unless absolutely necessary and the potential benefits outweigh the possible risks. Do not take the medicine without a doctor’s advice.

  • Shipping Options

    Registered Mail  USD 15.00

    Registered Mail (14-21 business days). No online tracking is available.

    EMS  USD 25.00

    EMS (5-9 business days). Online tracking is available!

  • Testimonials

Leave Your Comment